Organoids Market

Report Overview

The global organoids market was pegged at US$ 691.32 million in 2021 and is expected to witness a CAGR of 21.67 % during the forecast period. 

Market Fundamentals 

Organoids are three-dimensional miniature of stem cell derived tissue culture. It represents the simplified version of realistic micro-anatomy. It can be derived by direct differentiation of pluripotent stem cells or organ specific adult stem cells. Given the rapid advancements in life science, conventional methods of drug discovery are less useful and insufficient. In this way, it is anticipated that organoids will generate a sizeable revenue share in the years to come as a result of the expansion of drug discovery applications. Organoids can recognize the target and non-target actions and interactions of the candidate therapy for improved humanized therapies and pharmaceuticals. Having potential advantages over using animal models it is not only utilized in cancer research and drug discovery but also as regenerative medicine and therapeutic tool.

[4634534]

Market Dynamics

The market is expected to be driven by expanding acceptance of tailored pharmaceuticals, rising need for tumor modelling and biobanking, and growing attention to discovering alternatives to animal testing models. The possibility for using organoids as cell treatments and future replacements for whole-organ transplantation has been greatly increased by the development of 3D cell cultures that mimic human organs. Organoids are anticipated to be used more frequently in the upcoming years as the trend toward personalized therapy grows. However, despite the promising characteristics of organoids, their wide range of applications is constrained by several obstacles that still need to be overcome. These obstacles include a lack of high-fidelity cell types, restricted maturation, and abnormal physiology all of which may reduce their dependability for applications. Moreover, problems with integrating organoids into current workflows and a shortage of skilled workers are likely to have a detrimental effect on market expansion. The industry is predicted to expand faster as organoid cultures are increasingly used to analyze the mechanisms underlying human-specific illnesses.

Market Ecosystem

The global organoids market has been analyzed from four perspectives: product, application, source, end user, and region

Organoids Market by Product 

[567456]

The market has been divided into hepatic organoid, intestinal organoid, pancreatic organoid, colorectal organoid, neural organoid, and others based on product distribution. The most dominating category is hepatic organoids. The market is observing a rising demand to address the hepatic damages due to the rise in alcohol consumption, diabetes, and obesity, as well as the number of disorders linked with the liver. One of the recommended therapies for a patient with liver failure due to any type of cirrhosis is a liver transplant. Therefore, the industry for the hepatic organoid model is undoubtedly expanding given the increased demand for and likelihood of success of surgical intervention among other organs.

Organoids Market by Type

Based on type, the market for organoids is divided into intestine, stomach, liver brain, pancreas, kidney, lung and others. The market share leader is the intestinal category. Due to the development of numerous experimental procedures used in conjunction with intestinal organoid cultures and their anticipated dominance of the market from a scientific point of view. Additionally, it is projected that the kidney segment will expand at a high CAGR during the forecast period.

Organoids Market by Application

The worldwide organoids market is divided into various application categories, bio-banking, biomedical research and drug discovery, regenerative medicine, cancer research, therapeutic tools, and developmental biology. The organoids market sector for developmental biology held major share in 2021 since it is regarded as a main investigative study instrument of the human developmental biology, this market sector is likewise anticipated to dominate by 2030. Organoids created from embryonic stem cells also provide a thorough grasp of how the embryo develops as well as information on how stem cells develop.

Organoids Market by Source 

The adult stem cells specialized to organs and pluripotent stem cells are the two sources that make up the worldwide organoids market. Pluripotent stem cells accounted for major market share in 2021. Since induced pluripotent stem cells are regarded as a crucial resource for regenerative medicine to replace diseased or damaged tissues, this sector is also anticipated to dominate the market over the forecast period. In addition, there are several biological uses for induced pluripotent stem cells, including fundamental research, pharmacological testing, toxicological analysis, disease modelling, and cell therapy.

Organoids Market by End User

Based on end user, the market has been segmented into biopharmaceutical companies, contract research organizations, academics and research Institutes. The biopharmaceutical companies are identified to dominate the organoids market with highest share during the forecast period. The growth of the segment can be attributed to the frequent visits of patients to hospitals for diagnosis and treatment of various cellular as well as organ disorders.

Organoids Market by Region

The global organoids market has been divided into four geographic segments: North America, Europe, Asia Pacific, and the Rest of the World. The organoids market was dominated by North America, followed by Europe and Asia Pacific. The early approval of products generated from plasma and the rising use of organoids in numerous therapeutic fields are some of the factors responsible for North America's significant market share in the world. Recently, using human organoid culture technology, STEMCELL Technologies, Inc. conducted projects in collaboration with the University of British Columbia (UBC) at Genome British Columbia in April 2021 to test thousands of FDA-approved medications and clinical-stage drugs individually or in combination for drug repurposing against the SARS-CoV-2 infection.

Competitive Landscape

Some of the leader companies operating in the organoids market are Thermo Fisher Scientific Inc., Merck KGaA, QIAGEN N.V., GenScript, Promega Corporation, Takara Bio Inc., MERIDIAN BIOSCIENCE Inc., New England Biolabs, Agilent Technologies Inc., Mirus Bio LLC, Sino Biological Inc., and Hubrecht Organoid Technology among others.

Strategic Development

• In January 2021, BIOIVT (US) partnered with Upcyte Technologies GmbH (Germany) as the exclusive commercial worldwide distributor for its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).
• In May 2020, the researchers from the Luxembourg Center for System Biomedicine successfully derived organoids to be used I Parkinson’s disease.

Frequently Asked Questions About This Report